STOCK TITAN

Vigil Neuroscience, Inc. - VIGL STOCK NEWS

Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.

Vigil Neuroscience, Inc. (VIGL) is a pioneering biopharmaceutical company dedicated to developing microglia-focused therapeutics. These specialized treatments aim to treat both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Vigil Neuroscience leverages modern neuroscience drug development tools to create precision-based therapies that significantly improve the quality of life for patients and their families.

One of the company's key initiatives is the clinical development of iluzanebart, which is currently in a Phase 2 Proof of Concept (PoC) trial named IGNITE. This is the first-ever interventional trial targeting Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) patients, marking a critical advancement in the treatment landscape for this rare disease. In addition, the company is working on VG-3927, an orally available small molecule TREM2 agonist designed to treat more common neurodegenerative diseases associated with microglial dysfunction.

Vigil Neuroscience has also made notable strides in community engagement and support. Their comprehensive patient support initiatives include the ALSPAware program, which offers no-cost genetic testing and counseling. This program aims to reduce the barriers to accurate diagnosis and enable better disease management for ALSP patients.

Recent research presented by the company has revealed significant findings on the diagnostic challenges faced by the ALSP community. For instance, a retrospective analysis disclosed that only 24.7 percent of ALSP patients received an accurate initial diagnosis, with many being misdiagnosed with multiple sclerosis (MS) due to similar early symptoms. Vigil Neuroscience's ongoing research aims to provide better diagnostic tools and treatment options, thereby improving the overall patient journey.

Additionally, Vigil Neuroscience has been actively presenting its latest findings and achievements at various conferences. Recent presentations have highlighted the potential of VG-3927 to treat neurodegenerative diseases like Alzheimer's Disease (AD), showcasing its neuroprotective profile and ability to favorably modulate microglia activation.

As Vigil Neuroscience continues to advance its clinical programs and expand its therapeutic pipeline, it remains committed to delivering innovative solutions that address the unmet needs of patients suffering from neurodegenerative diseases.

Rhea-AI Summary
Vigil Neuroscience to participate in fireside chat at Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.18%
Tags
conferences
-
Rhea-AI Summary
Vigil Neuroscience receives positive opinion for orphan drug designation for VGL101 in EU for the treatment of CSF1R-related leukoencephalopathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
Vigil Neuroscience announces positive Phase 1 data analysis for VGL101, on track to report interim data from IGNITE trial in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
Rhea-AI Summary
Vigil Neuroscience announces lead candidate for Alzheimer's Disease treatment, IND for VG-3927 now open, Phase 1 trial to proceed with partial clinical hold. Phase 1 dosing expected in October 2023. Company to host virtual R&D event on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
Rhea-AI Summary
Vigil Neuroscience to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
management

FAQ

What is the current stock price of Vigil Neuroscience (VIGL)?

The current stock price of Vigil Neuroscience (VIGL) is $3.19 as of November 22, 2024.

What is the market cap of Vigil Neuroscience (VIGL)?

The market cap of Vigil Neuroscience (VIGL) is approximately 132.3M.

What is the primary focus of Vigil Neuroscience, Inc.?

Vigil Neuroscience focuses on developing therapeutics that target microglia to treat rare and common neurodegenerative diseases.

What is iluzanebart?

Iluzanebart is a clinical candidate being studied in a Phase 2 PoC trial called IGNITE, targeting patients with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP).

What is VG-3927?

VG-3927 is an orally available small molecule TREM2 agonist under development for treating common neurodegenerative diseases associated with microglial dysfunction.

What is the ALSPAware program?

The ALSPAware program offers no-cost genetic testing and counseling to facilitate accurate diagnosis and better disease management for ALSP patients.

What recent findings has Vigil Neuroscience presented?

Vigil Neuroscience has presented data on diagnostic challenges in ALSP and the potential of VG-3927 to treat neurodegenerative diseases like Alzheimer's Disease.

How does Vigil Neuroscience contribute to the neurodegenerative disease community?

Vigil Neuroscience contributes through clinical research, patient support programs, and the development of innovative therapies targeting microglial dysfunction.

What is the IGNITE trial?

The IGNITE trial is a Phase 2 PoC clinical study investigating iluzanebart for treating ALSP patients.

Why is microglia important in neurodegenerative diseases?

Microglia are the sentinel cells of the brain's immune system, and their dysfunction is linked to various neurodegenerative conditions. Restoring their vigilance can mitigate disease progression.

What challenges do ALSP patients face in terms of diagnosis?

ALSP patients often face misdiagnosis, with multiple sclerosis (MS) being a common incorrect diagnosis due to similar early symptoms.

Who can I contact for investor and media inquiries?

For investor inquiries, contact Leah Gibson, Vice President of Investor Relations & Corporate Communications at lgibson@vigilneuro.com. For media inquiries, contact Megan McGrath at MacDougall Advisors via email at mmcgrath@macdougall.bio.

Vigil Neuroscience, Inc.

Nasdaq:VIGL

VIGL Rankings

VIGL Stock Data

132.28M
32.00M
21.27%
80.16%
1.29%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN